1,300 results on '"Mentz, Robert J"'
Search Results
2. The need for increased pragmatism in cardiovascular clinical trials
- Author
-
Usman, Muhammad Shariq, Van Spall, Harriette GC, Greene, Stephen J, Pandey, Ambarish, McGuire, Darren K, Ali, Ziad A, Mentz, Robert J, Fonarow, Gregg C, Spertus, John A, Anker, Stefan D, Butler, Javed, James, Stefan K, and Khan, Muhammad Shahzeb
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Comparative Effectiveness Research ,Cardiovascular ,Heart Disease ,Clinical Trials and Supportive Activities ,Prevention ,Clinical Research ,Good Health and Well Being ,Cardiovascular Diseases ,Humans ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
The majority of cardiovascular randomized controlled trials (RCTs) test interventions in selected patient populations under explicitly protocol-defined settings. Although these 'explanatory' trial designs optimize conditions to test the efficacy and safety of an intervention, they limit the generalizability of trial findings in broader clinical settings. The concept of 'pragmatism' in RCTs addresses this concern by providing counterbalance to the more idealized situation underpinning explanatory RCTs and optimizing effectiveness over efficacy. The central tenets of pragmatism in RCTs are to test interventions in routine clinical settings, with patients who are representative of broad clinical practice, and to reduce the burden on investigators and participants by minimizing the number of trial visits and the intensity of trial-based testing. Pragmatic evaluation of interventions is particularly important in cardiovascular diseases, where the risk of death among patients has remained fairly stable over the past few decades despite the development of new therapeutic interventions. Pragmatic RCTs can help to reveal the 'real-world' effectiveness of therapeutic interventions and elucidate barriers to their implementation. In this Review, we discuss the attributes of pragmatism in RCT design, conduct and interpretation as well as the general need for increased pragmatism in cardiovascular RCTs. We also summarize current challenges and potential solutions to the implementation of pragmatism in RCTs and highlight selected ongoing and completed cardiovascular RCTs with pragmatic trial designs.
- Published
- 2022
3. Carbon emissions and air pollution savings among telehealth visits for cardiology appointments
- Author
-
Gunn, Alexander H., Murray, Evan M., Patel, Manesh R., and Mentz, Robert J.
- Published
- 2024
- Full Text
- View/download PDF
4. Effects of Sacubitril/Valsartan vs Valsartan in De Novo vs Acute on Chronic HFpEF and HFmrEF
- Author
-
Murray, Evan M., Cyr, Derek, Fudim, Marat, Ward, Jonathan H., Hernandez, Adrian F., Lepage, Serge, Morrow, David A., Starling, Randall C., Williamson, Kristin M., Desai, Akshay S., Zieroth, Shelley, Solomon, Scott D., and Mentz, Robert J.
- Published
- 2024
- Full Text
- View/download PDF
5. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review
- Author
-
Mentz, Robert J., Brunton, Stephen A., and Rangaswami, Janani
- Published
- 2023
- Full Text
- View/download PDF
6. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials JACC Review Topic of the Week
- Author
-
Fiuzat, Mona, Hamo, Carine E, Butler, Javed, Abraham, William T, DeFilippis, Ersilia M, Fonarow, Gregg C, Lindenfeld, Joann, Mentz, Robert J, Psotka, Mitchell A, Solomon, Scott D, Teerlink, John R, Vaduganathan, Muthiah, Vardeny, Orly, McMurray, John JV, and O’Connor, Christopher M
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Heart Disease ,Cardiovascular ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Cardiovascular Agents ,Clinical Trials as Topic ,Heart Failure ,Humans ,Periodicals as Topic ,Stroke Volume ,clinical trials ,device therapy ,drug therapy ,FDA ,guideline directed ,medical therapy ,heart failure ,HFrEF ,medication ,guideline directed medical therapy ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
With the current landscape of approved therapies for heart failure (HF), there is a need to determine the role of a standard background therapy against which novel therapies are studied. The Heart Failure Collaboratory convened a multistakeholder group of clinical investigators, clinicians, patients, government representatives including U.S. Food and Drug Administration and National Institutes of Health participants, payers, and industry in March 2021 to discuss whether standardization of background drug therapy is necessary in clinical trials in patients with HF. The current paper summarizes the discussion and provides potential conceptual approaches, with a focus on therapies indicated for HF with reduced ejection fraction.
- Published
- 2022
7. In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction
- Author
-
Rao, Vishal N, Murray, Evan, Butler, Javed, Cooper, Lauren B, Cox, Zachary L, Fiuzat, Mona, Green, Jennifer B, Lindenfeld, JoAnn, McGuire, Darren K, Nassif, Michael E, O'Brien, Cara, Pagidipati, Neha, Sharma, Kavita, Vaduganathan, Muthiah, Vardeny, Orly, Fonarow, Gregg C, Mentz, Robert J, and Greene, Stephen J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Cardiovascular ,Heart Disease ,Clinical Research ,Patient Safety ,5.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Development of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Diabetes Mellitus ,Type 2 ,Heart Failure ,Hospitalization ,Humans ,Hypoglycemic Agents ,Patient Discharge ,Patient Readmission ,Patient-Centered Care ,Practice Guidelines as Topic ,Randomized Controlled Trials as Topic ,Risk ,Sodium-Glucose Transporter 2 ,Sodium-Glucose Transporter 2 Inhibitors ,Stroke Volume ,Ventricular Dysfunction ,Left ,  ,guideline-directed medical therapy ,heart failure ,in-hospital prescribing ,medical therapy ,sodium-glucose cotransporter-2 inhibitors ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
Sodium-glucose cotransporter-2 inhibitor therapy is well suited for initiation during the heart failure hospitalization, owing to clinical benefits that accrue rapidly within days to weeks, a strong safety and tolerability profile, minimal to no effects on blood pressure, and no excess risk of adverse kidney events. There is no evidence to suggest that deferring initiation to the outpatient setting accomplishes anything beneficial. Instead, there is compelling evidence that deferring in-hospital initiation exposes patients to excess risk of early postdischarge clinical worsening and death. Lessons from other heart failure with reduced ejection fraction therapies highlight that deferring initiation of guideline-recommended medications to the U.S. outpatient setting carries a >75% chance they will not be initiated within the next year. Recognizing that 1 in 4 patients hospitalized for worsening heart failure die or are readmitted within 30 days, clinicians should embrace the in-hospital period as an optimal time to initiate sodium-glucose cotransporter-2 inhibitor therapy and treat this population with the urgency it deserves.
- Published
- 2021
8. Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction JACC State-of-the-Art Review
- Author
-
Pandey, Ambarish, Shah, Sanjiv J, Butler, Javed, Kellogg, Dean L, Lewis, Gregory D, Forman, Daniel E, Mentz, Robert J, Borlaug, Barry A, Simon, Marc A, Chirinos, Julio A, Fielding, Roger A, Volpi, Elena, Molina, Anthony JA, Haykowsky, Mark J, Sam, Flora, Goodpaster, Bret H, Bertoni, Alain G, Justice, Jamie N, White, James P, Ding, Jingzhone, Hummel, Scott L, LeBrasseur, Nathan K, Taffet, George E, Pipinos, Iraklis I, and Kitzman, Dalane
- Subjects
Aging ,Heart Disease ,Cardiovascular ,Animals ,Exercise Tolerance ,Heart Failure ,Diastolic ,Humans ,exercise intolerance ,heart failure with preserved ejection fraction ,senescence ,skeletal muscle ,aging ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology - Abstract
Exercise intolerance (EI) is the primary manifestation of chronic heart failure with preserved ejection fraction (HFpEF), the most common form of heart failure among older individuals. The recent recognition that HFpEF is likely a systemic, multiorgan disorder that shares characteristics with other common, difficult-to-treat, aging-related disorders suggests that novel insights may be gained from combining knowledge and concepts from aging and cardiovascular disease disciplines. This state-of-the-art review is based on the outcomes of a National Institute of Aging-sponsored working group meeting on aging and EI in HFpEF. We discuss aging-related and extracardiac contributors to EI in HFpEF and provide the rationale for a transdisciplinary, "gero-centric" approach to advance our understanding of EI in HFpEF and identify promising new therapeutic targets. We also provide a framework for prioritizing future research, including developing a uniform, comprehensive approach to phenotypic characterization of HFpEF, elucidating key geroscience targets for treatment, and conducting proof-of-concept trials to modify these targets.
- Published
- 2021
9. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
- Author
-
Greene, Stephen J, Choi, Sujung, Lippmann, Steven J, Mentz, Robert J, Greiner, Melissa A, Hardy, N Chantelle, Hammill, Bradley G, Luo, Nancy, Samsky, Marc D, Heidenreich, Paul A, Laskey, Warren K, Yancy, Clyde W, Peterson, Pamela N, Curtis, Lesley H, Hernandez, Adrian F, Fonarow, Gregg C, and O'Brien, Emily C
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Heart Disease ,Cardiovascular ,Aging ,Clinical Trials and Supportive Activities ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Aged ,Aged ,80 and over ,Aminobutyrates ,Angiotensin II Type 1 Receptor Blockers ,Biphenyl Compounds ,Drug Combinations ,Female ,Heart Failure ,Hospitalization ,Humans ,Male ,Medicare ,Neprilysin ,Patient Discharge ,Protease Inhibitors ,Registries ,Risk Assessment ,Risk Factors ,Stroke Volume ,Time Factors ,Treatment Outcome ,United States ,Valsartan ,Ventricular Function ,Left ,heart failure ,reduced ejection fraction ,registry ,sacubitril ,valsartan ,sacubitril/valsartan ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure with reduced ejection fraction (HFrEF). However, the effectiveness of sacubitril/valsartan in older patients hospitalized for HFrEF in real-world US practice is unclear. Methods and Results This study included Medicare beneficiaries age ≥65 years who were hospitalized for HFrEF ≤40% in the Get With The Guidelines-Heart Failure registry between October 2015 and December 2018, and eligible for sacubitril/valsartan. Associations between discharge prescription of sacubitril/valsartan and clinical outcomes were assessed after inverse probability of treatment weighting and adjustment for other HFrEF medications. Overall, 1551 (10.9%) patients were discharged on sacubitril/valsartan. Of those not prescribed sacubitril/valsartan, 7857 (62.0%) were prescribed an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker. Over 12-month follow-up, compared with a discharge prescription of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker, sacubitril/valsartan was independently associated with lower all-cause mortality (adjusted hazard ratio [HR], 0.82; 95% CI, 0.72-0.94; P=0.004) but not all-cause hospitalization (adjusted HR, 0.97; 95% CI, 0.89-1.07; P=0.55) or heart failure hospitalization (adjusted HR, 1.04; 95% CI, 0.91-1.18; P=0.59). Patients prescribed sacubitril/valsartan versus those without a prescription had lower risk of all-cause mortality (adjusted HR, 0.69; 95% CI, 0.60-0.79; P
- Published
- 2021
10. Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3
- Author
-
Greene, Stephen J., Bauersachs, Johann, Brugts, Jasper J., Ezekowitz, Justin A., Filippatos, Gerasimos, Gustafsson, Finn, Lam, Carolyn S.P., Lund, Lars H., Mentz, Robert J., Pieske, Burkert, Ponikowski, Piotr, Senni, Michele, Skopicki, Natalie, Voors, Adriaan A., Zannad, Faiez, Zieroth, Shelley, and Butler, Javed
- Published
- 2023
- Full Text
- View/download PDF
11. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure
- Author
-
Mentz, Robert J., Ward, Jonathan H., Hernandez, Adrian F., Lepage, Serge, Morrow, David A., Sarwat, Samiha, Sharma, Kavita, Starling, Randall C., Velazquez, Eric J., Williamson, Kristin M., Desai, Akshay S., Zieroth, Shelley, Solomon, Scott D., and Braunwald, Eugene
- Published
- 2023
- Full Text
- View/download PDF
12. Palliative Care for Patients With Heart Failure With Preserved Ejection Fraction
- Author
-
Godfrey, Sarah, Peng, Yilong, Lorusso, Nicholas, Sulistio, Melanie, Mentz, Robert J., Pandey, Ambarish, and Warraich, Haider
- Published
- 2023
- Full Text
- View/download PDF
13. Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel
- Author
-
Psotka, Mitchell A., Abraham, William T., Fiuzat, Mona, Filippatos, Gerasimos, Lindenfeld, JoAnn, Ahmad, Tariq, Felker, G. Michael, Jacob, Richard, Kitzman, Dalane W., Leifer, Eric S., Lewis, Eldrin F., Mentz, Robert J., Nkulikiyinka, Richard, Ni, Wei, Schaber, Daniel E., Sharma, Abhinav, Solomon, Scott D., Stockbridge, Norman, Teerlink, John R., Unger, Ellis F., Whellan, David J., Wittes, Janet, Anker, Stefan D., and O’Connor, Christopher M.
- Published
- 2022
- Full Text
- View/download PDF
14. Obesity Status and Physical Rehabilitation in Older Patients Hospitalized With Acute HF: Insights From REHAB-HF
- Author
-
Peters, Anthony E., Kitzman, Dalane W., Chen, Haiying, Nelson, M. Benjamin, Pastva, Amy M., Duncan, Pamela W., Reeves, Gordon R., Upadhya, Bharathi, Whellan, David J., and Mentz, Robert J.
- Published
- 2022
- Full Text
- View/download PDF
15. Representativeness of a Heart Failure Trial by Race and Sex Results From ASCEND-HF and GWTG-HF
- Author
-
Greene, Stephen J, DeVore, Adam D, Sheng, Shubin, Fonarow, Gregg C, Butler, Javed, Califf, Robert M, Hernandez, Adrian F, Matsouaka, Roland A, Samman Tahhan, Ayman, Thomas, Kevin L, Vaduganathan, Muthiah, Yancy, Clyde W, Peterson, Eric D, O'Connor, Christopher M, and Mentz, Robert J
- Subjects
Heart Disease ,Clinical Research ,Clinical Trials and Supportive Activities ,Cardiovascular ,Good Health and Well Being ,Black or African American ,Aged ,Aged ,80 and over ,Female ,Heart Failure ,Humans ,Male ,Natriuretic Agents ,Natriuretic Peptide ,Brain ,Patient Selection ,Randomized Controlled Trials as Topic ,Sex Distribution ,White People ,enrollment ,heart failure ,race ,sex ,trial ,Cardiorespiratory Medicine and Haematology - Abstract
ObjectivesThis study sought to determine the degree to which U.S. patients enrolled in a heart failure (HF) trial represent patients in routine U.S. clinical practice according to race and sex.BackgroundBlack patients and women are frequently under-represented in HF clinical trials. However, the degree to which black patients and women enrolled in trials represent such patients in routine practice is unclear.MethodsThe ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial randomized patients hospitalized for HF to receive nesiritide or placebo from May 2007 to August 2010 and was neutral for clinical endpoints. This analysis compared non-Hispanic white (n = 1,494) and black (n = 1,012) patients enrolled in ASCEND-HF from the U.S. versus non-Hispanic white and black patients included in a U.S. hospitalized HF registry (i.e., Get With The Guidelines-Heart Failure [GWTG-HF]) during the ASCEND-HF enrollment period and meeting trial eligibility criteria.ResultsAmong 79,291 white and black registry patients, 49,063 (62%) met trial eligibility criteria (white, n = 37,883 [77.2%]; black, n = 11,180 [22.8%]). Women represented 35% and 49% of the ASCEND-HF and trial-eligible GWTG-HF cohorts, respectively. Compared with trial-enrolled patients, trial-eligible GWTG-HF patients tended to be older with higher blood pressure and higher ejection fraction. Trial-eligible patients had higher in-hospital mortality (2.3% vs. 1.3%), 30-day readmission (20.2% vs. 16.8%), and 180-day mortality (21.2% vs. 18.6%) than those enrolled in the trial (all p
- Published
- 2019
16. Relationship Between Hospital Characteristics and Early Adoption of Angiotensin‐Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure
- Author
-
Luo, Nancy, Lippmann, Steven J, Mentz, Robert J, Greiner, Melissa A, Hammill, Bradley G, Hardy, N Chantelle, Laskey, Warren K, Heidenreich, Paul A, Chang, Chun‐Lan, Hernandez, Adrian F, Curtis, Lesley H, Peterson, Pamela N, Fonarow, Gregg C, and O'Brien, Emily C
- Subjects
Clinical Research ,Heart Disease ,Cardiovascular ,Aged ,Aged ,80 and over ,Aminobutyrates ,Angiotensin Receptor Antagonists ,Biphenyl Compounds ,Drug Combinations ,Female ,Follow-Up Studies ,Heart Failure ,Hospital Mortality ,Hospitalization ,Humans ,Male ,Medication Adherence ,Middle Aged ,Neprilysin ,Registries ,Retrospective Studies ,Stroke Volume ,Survival Rate ,Tetrazoles ,Treatment Outcome ,United States ,Valsartan ,early adoption ,implementation science ,novel therapy ,quality improvement ,Cardiorespiratory Medicine and Haematology - Abstract
Background The angiotensin-receptor/neprilysin inhibitor ( ARNI ) sacubitril/valsartan reduces hospitalization and mortality for patients with heart failure with reduced ejection fraction. However, adoption of ARNI into clinical practice has been slow. Factors influencing use of ARNI have not been fully elucidated. Using data from the Get With The Guidelines-Heart Failure registry, Hospital Compare, Dartmouth Atlas, and the American Hospital Association Survey, we sought to identify hospital characteristics associated with patient-level receipt of an ARNI prescription. Methods and Results We analyzed patients with heart failure with reduced ejection fraction who were eligible for ARNI prescription (ejection fraction≤40%, no contraindications) and hospitalized from October 1, 2015 through December 31, 2016. We used logistic regression to estimate the associations between hospital characteristics and patient ARNI prescription at hospital discharge, accounting for clustering of patients within hospitals using generalized estimating equation methods and adjusting for patient-level covariates. Of 16 674 eligible hospitalizations from 210 hospitals, 1020 patients (6.1%) were prescribed ARNI at discharge. The median hospital-level proportion of patients prescribed ARNI was 3.3% (Q1, Q3: 0%, 12.6%). After adjustment for patient-level covariates, for-profit hospitals had significantly higher odds of ARNI prescription compared with not-for-profit hospitals (odds ratio, 2.53; 95% CI , 1.05-6.10; P=0.04), and hospitals located in the Western United States had lower odds of ARNI prescription compared with those in the Northeast (odds ratio, 0.33; 95% CI , 0.13-0.84; P=0.02). Conclusions Relatively few hospital characteristics were associated with ARNI prescription at hospital discharge, in contrast to what has been observed in early adoption in other disease areas. Additional evaluation of barriers to implementing new evidence into heart failure practice is needed.
- Published
- 2019
17. Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes.
- Author
-
Goldstein, Sarah A, Mentz, Robert J, Hellkamp, Anne S, Randolph, Tiffany C, Fonarow, Gregg C, Hernandez, Adrian, Yancy, Clyde W, and Al-Khatib, Sana M
- Subjects
Humans ,Treatment Outcome ,Severity of Illness Index ,Survival Rate ,Retrospective Studies ,Follow-Up Studies ,Time Factors ,Aged ,Aged ,80 and over ,United States ,Female ,Male ,Heart Failure ,Cardiac Resynchronization Therapy ,Cardiac Resynchronization Therapy Devices ,CRT ,cardiac resynchronization therapy ,heart failure ,mortality ,outcomes ,re-hospitalization ,and over ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology - Abstract
BackgroundWhen used in appropriately selected heart failure (HF) patients, cardiac resynchronization therapy (CRT) reduces mortality and hospitalization. It is not understood whether CRT implantation during hospitalization for HF is associated with similar benefits.HypothesisTiming of CRT implantation relative to hospitalization for HF is associated with clinical outcomes.MethodsThis analysis included patients eligible for CRT and discharged alive between January 2005 and December 2012 from 388 hospitals in Get With The Guidelines-HF. Participants were linked with Centers for Medicare and Medicaid Services data to evaluate outcomes of all-cause mortality and HF re-hospitalization based on CRT status (present on admission, placed during hospitalization, and prescribed at discharge; reference = no CRT).ResultsOf 15 619 CRT-eligible HF patients, 2408 (15%) had CRT on admission, 1269 (8%) underwent CRT implantation during hospitalization and 643 (4%) had CRT prescribed at discharge. Compared with patients without CRT, mortality was lower in those who received CRT implantation during HF hospitalization (adjusted hazard ratio [HR] 0.63; P < 0.0001) and those prescribed CRT at discharge (adjusted HR 0.78; P = 0.048). A reduction in HF re-hospitalization was observed in patients with CRT implanted during hospitalization (adjusted HR 0.64; P < 0.0001), but not in those who were prescribed CRT at discharge (adjusted HR 1.02; P = 0.77).ConclusionCRT implantation during HF hospitalization was associated with lower rates of mortality and HF re-hospitalization. These data suggest that a CRT utilization strategy that does not delay implantation to the post-discharge period may be appropriate. Randomized data are needed to definitively identify optimal timing of CRT implantation.
- Published
- 2019
18. Trends in Heart Failure–Related Mortality Among Older Adults in the United States From 1999-2019
- Author
-
Siddiqi, Tariq Jamal, Khan Minhas, Abdul Mannan, Greene, Stephen J., Van Spall, Harriette G.C., Khan, Sadiya S., Pandey, Ambarish, Mentz, Robert J., Fonarow, Gregg C., Butler, Javed, and Khan, Muhammad Shahzeb
- Published
- 2022
- Full Text
- View/download PDF
19. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
- Author
-
Greene, Stephen J., Velazquez, Eric J., Anstrom, Kevin J., Clare, Robert M., DeWald, Tracy A., Psotka, Mitchell A., Ambrosy, Andrew P., Stevens, Gerin R., Rommel, John J., Alexy, Tamas, Ketema, Fassil, Kim, Dong-Yun, Desvigne-Nickens, Patrice, Pitt, Bertram, Eisenstein, Eric L., and Mentz, Robert J.
- Published
- 2023
- Full Text
- View/download PDF
20. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
- Author
-
Voors, Adriaan A., Angermann, Christiane E., Teerlink, John R., Collins, Sean P., Kosiborod, Mikhail, Biegus, Jan, Ferreira, João Pedro, Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Borleffs, C. Jan Willem, Ma, Changsheng, Comin-Colet, Joseph, Fu, Michael, Janssens, Stefan P., Kiss, Robert G., Mentz, Robert J., Sakata, Yasushi, Schirmer, Henrik, Schou, Morten, Schulze, P. Christian, Spinarova, Lenka, Volterrani, Maurizio, Wranicz, Jerzy K., Zeymer, Uwe, Zieroth, Shelley, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, and Ponikowski, Piotr
- Published
- 2022
- Full Text
- View/download PDF
21. Patients phenotypes and cardiovascular risk in type 2 diabetes: the Jackson Heart Study
- Author
-
Echouffo-Tcheugui, Justin B., Musani, Solomon K., Bertoni, Alain G., Correa, Adolfo, Fox, Ervin R., and Mentz, Robert J.
- Published
- 2022
- Full Text
- View/download PDF
22. Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
- Author
-
Davis, Timothy M. E., Giczewska, Anna, Lokhnygina, Yuliya, Mentz, Robert J., Sattar, Naveed, and Holman, Rury R.
- Published
- 2022
- Full Text
- View/download PDF
23. Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events
- Author
-
Regan, Jessica A., Truby, Lauren K., Tahir, Usman A., Katz, Daniel H., Nguyen, Maggie, Kwee, Lydia Coulter, Deng, Shuliang, Wilson, James G., Mentz, Robert J., Kraus, William E., Hernandez, Adrian F., Gerszten, Robert E., Peterson, Eric D., Holman, Rury R., and Shah, Svati H.
- Published
- 2022
- Full Text
- View/download PDF
24. Glycemic status, non-traditional risk and left ventricular structure and function in the Jackson Heart Study
- Author
-
Ani, Chizobam, Shavlik, David, Knutsen, Synnove, Abudayyeh, Islam, Banta, Jimmie, O’Brien, Emily, Mentz, Robert J., Bertoni, Alain G., and Fraser, Gary
- Published
- 2022
- Full Text
- View/download PDF
25. Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018
- Author
-
Jain, Vardhman, Minhas, Abdul Mannan Khan, Khan, Safi U., Greene, Stephen J., Pandey, Ambarish, Van Spall, Harriette G.C., Fonarow, Gregg C., Mentz, Robert J., Butler, Javed, and Khan, Muhammad Shahzeb
- Published
- 2022
- Full Text
- View/download PDF
26. Spirituality in Patients With Heart Failure
- Author
-
Tobin, Rachel S., Cosiano, Michael F., O’Connor, Christopher M., Fiuzat, Mona, Granger, Bradi B., Rogers, Joseph G., Tulsky, James A., Steinhauser, Karen E., and Mentz, Robert J.
- Published
- 2022
- Full Text
- View/download PDF
27. Implications of trial eligibility in patients with heart failure with mildly reduced or preserved ejection fraction.
- Author
-
Peters, Anthony E., Clare, Robert M., Chiswell, Karen, Harrington, Josephine, Kelsey, Anita, Hernandez, Adrian, Felker, Gary Michael, Mentz, Robert J., and DeVore, Adam D.
- Subjects
GLOBAL longitudinal strain ,TRANSIENT ischemic attack ,HEART failure patients ,PERIPHERAL vascular diseases ,NATRIURETIC peptides - Abstract
Aims: Clinical trials in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) commonly have detailed eligibility criteria. This may contribute to challenges with efficient enrolment and questions regarding the generalizability of trial findings. Methods and results: Patients with HFmrEF/HFpEF from a large US healthcare system were identified through a computable phenotype applied in linked imaging and electronic health record databases. We evaluated shared eligibility criteria from five recent/ongoing HFmrEF/HFpEF trials (PARAGON‐HF, EMPEROR‐Preserved, DELIVER, FINE‐ARTS, and SPIRRIT‐HFpEF) and compared clinical and echocardiographic features as well as outcomes between trial‐eligible and trial‐ineligible patients. Among 5552 patients with HFpEF/HFmrEF, 792 (14%) were eligible for trial consideration, having met all criteria assessed. Causes of ineligibility included lack of recent loop diuretics (37%), significant pulmonary disease (24%), reduced estimated glomerular filtration rate (17%), recent stroke/transient ischaemic attack (13%), or low natriuretic peptides (12%); 53% of ineligible patients had >1 reason for exclusion. Compared with eligible patients, ineligible patients were younger (age 71 vs. 75 years, P < 0.001) with higher rates of coronary artery disease (66% vs. 59%, P < 0.001) and peripheral vascular disease (40% vs. 33%, P < 0.001), but less mitral regurgitation, lower E/e′ ratio, and smaller left atrial sizes. Both eligible and ineligible patients demonstrated high rates of structural heart disease consistent with HFpEF [elevated left atrial size or left ventricular (LV) hypertrophy/increased LV mass], although this was slightly higher among eligible patients (95% vs. 92%, P = 0.001). The two cohorts demonstrated similar LV global longitudinal strain along with a similar prevalence of atrial fibrillation/flutter, hypertension, and obesity. Ineligible patients had similar all‐cause mortality (33% vs. 33% at 3 years) to those eligible but lower rates of heart failure hospitalization (20% vs. 28% at 3 years, P < 0.001). Conclusions: Among patients with HFmrEF/HFpEF from a large health system, approximately one in seven were eligible for major trials based on key criteria applied through a clinical computable phenotype. These findings highlight the large proportion of patients with HFmrEF/HFpEF ineligible for contemporary trials for whom the generalizability of trial findings may be questioned and further investigation would be beneficial. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Depressive symptoms are associated with clinical outcomes in heart failure with reduced ejection fraction.
- Author
-
Sherwood, Andrew, Blumenthal, James A., Mentz, Robert J., Koch, Gary G., Rogers, Joseph G., Chang, Patricia P., Chien, Christopher, Adams, Kirkwood F., Rose‐Jones, Lisa J., Jensen, Brian C., Donahue, Mark, Johnson, Kristy S., and Hinderliter, Alan L.
- Subjects
PROPORTIONAL hazards models ,SYMPTOMS ,MENTAL depression ,HEART failure patients ,HEALTH behavior ,HEART failure - Abstract
Aims: The objective of this study was to examine associations between elevated depressive symptoms and increased risk of adverse clinical events patients with heart failure and reduced ejection fraction (HFrEF), as well as the potential contribution of health behaviours. Methods and results: One hundred forty‐two men and women with HFrEF were enrolled through heart failure (HF) clinics and followed over time. At baseline and 6 months, depressive symptoms were assessed by the Beck Depression Inventory‐II (BDI‐II) and HFrEF disease activity by B‐type natriuretic peptide (BNP). The Self‐Care of Heart Failure Index (SCHFI) was used to assess HF self‐care behaviours. Proportional hazards regression models assessed the contribution of depressive symptoms and HFrEF disease biomarkers on death or cardiovascular hospitalization. Over a median follow‐up period of 4 years, 42 patients (30%) died, and 84 (60%) had cardiovascular hospitalizations. A 10‐point higher baseline BDI‐II score was associated with a 35% greater risk of death or cardiovascular hospitalization. Higher baseline BDI‐II scores were associated with poorer HF self‐care maintenance behaviours (R = −0.30, P < 0.001) and fewer daily steps (R = −0.19, P = 0.04), suggesting that elevated depressive symptoms may diminish important health behaviours. Increases in plasma BNP over 6 months were associated with worse outcomes. Changes in BDI‐II and plasma BNP over 6 months were positively related (R = 0.25, P = 0.004). Conclusions: This study confirms that elevated depressive symptoms are associated with an increased likelihood of adverse clinical outcomes in patients with HFrEF. Poor health behaviours may contribute to the adverse association of elevated depressive symptoms with the increased hazard of adverse clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults
- Author
-
Coniglio, Amanda C., Segar, Matthew W., Loungani, Rahul S., Savla, Jainy J., Grodin, Justin L., Fox, Ervin R., Garg, Sonia, de Lemos, James A., Berry, Jarett D., Drazner, Mark H., Shah, Sanjiv, Hall, Michael E., Shah, Amil, Khan, Sadiya S., Mentz, Robert J., and Pandey, Ambarish
- Published
- 2022
- Full Text
- View/download PDF
30. New Paradigms to Address Long-Term Exercise Adherence, An Achilles Heel of Lifestyle Interventions
- Author
-
Peters, Anthony E., Kraus, William E., and Mentz, Robert J.
- Published
- 2023
- Full Text
- View/download PDF
31. Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation
- Author
-
Luo, Nancy, Xu, Haolin, Jneid, Hani, Fonarow, Gregg C, Lopes, Renato D, Piccini, Jonathan P, Curtis, Anne B, Russo, Andrea M, Lewis, William R, Matsouaka, Roland A, Granger, Christopher B, Mentz, Robert J, and Al-Khatib, Sana M
- Subjects
Heart Disease ,Cardiovascular ,Clinical Research ,Administration ,Oral ,Anticoagulants ,Atrial Fibrillation ,Female ,Heart Failure ,Humans ,Patient Discharge ,Practice Patterns ,Physicians' ,Risk Factors ,Warfarin ,direct thrombin inhibitors ,factor Xa inhibitors ,outcomes research ,quality improvement ,stroke ,Biochemistry and Cell Biology ,Cardiorespiratory Medicine and Haematology ,Medical Physiology ,Cardiovascular System & Hematology - Abstract
BackgroundStroke prophylaxis in patients with atrial fibrillation (AF) and heart failure (HF) in the era of direct oral anticoagulants is not well characterized. Using data from American Heart Association Get With The Guidelines-AFIB, we sought to evaluate oral anticoagulation (OAC) use at discharge among AF patients with concomitant HF.Methods and resultsAF patients with a diagnosis of HF hospitalized from January 2013 to March 2017 were included. We compared patient characteristics and use of OAC at discharge among patients with reduced (redundant ejection fraction [EF], EF≤40%), borderline (40%2DS2-VASc score was 5 (Q1, Q3; 3, 6) among all patients and higher among those with HF with preserved EF than HF with reduced EF (5 [4, 6] versus 4 [3, 5]; P
- Published
- 2018
32. Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure
- Author
-
Greene, Stephen J, Mentz, Robert J, Fiuzat, Mona, Butler, Javed, Solomon, Scott D, Ambrosy, Andrew P, Mehta, Cyrus, Teerlink, John R, Zannad, Faiez, and O'Connor, Christopher M
- Subjects
Clinical Trials and Supportive Activities ,Cardiovascular ,Clinical Research ,Heart Disease ,Cardiovascular Agents ,Clinical Trials ,Phase II as Topic ,Consensus ,Drug Development ,Endpoint Determination ,Heart Failure ,Humans ,Research Design ,Treatment Outcome ,biomarkers ,clinical trial ,drug discovery ,endpoint determination ,heart failure ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Public Health and Health Services ,Cardiovascular System & Hematology - Abstract
With few notable exceptions, drug development for heart failure (HF) has become progressively more challenging, and there remain no definitively proven therapies for patients with acute HF or HF with preserved ejection fraction. Inspection of temporal trends suggests an increasing rate of disagreement between early-phase and phase III trial end points. Preliminary results from phase II HF trials are frequently promising, but increasingly followed by disappointing phase III results. Given this potential disconnect, it is reasonable to carefully re-evaluate the purpose, design, and execution of phase II HF trials, with particular attention directed toward the surrogate end points commonly used by these studies. In this review, we offer a critical reappraisal of the role of phase II HF trials and surrogate end points, highlighting challenges in their use and interpretation, lessons learned from past experiences, and specific strengths and weaknesses of various surrogate outcomes. We conclude by proposing a series of approaches that should be considered for the goal of optimizing the efficiency of HF drug development. This review is based on discussions between scientists, clinical trialists, industry and government sponsors, and regulators that took place at the Cardiovascular Clinical Trialists Forum in Washington, DC, on December 2, 2016.
- Published
- 2018
33. Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND‐HF
- Author
-
Verma, Amanda K, Sun, Jie‐Lena, Hernandez, Adrian, Teerlink, John R, Schulte, Phillip J, Ezekowitz, Justin, Voors, Adriaan, Starling, Randall, Armstrong, Paul, O'Conner, Christopher M, and Mentz, Robert J
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Patient Safety ,Cardiovascular ,Aging ,Clinical Research ,Heart Disease ,Good Health and Well Being ,Aged ,Aged ,80 and over ,Alberta ,Blood Pressure ,Dose-Response Relationship ,Drug ,Female ,Heart Failure ,Heart Rate ,Humans ,Inpatients ,Male ,Middle Aged ,Natriuretic Agents ,Natriuretic Peptide ,Brain ,Netherlands ,Prognosis ,Stroke Volume ,Survival Rate ,United States ,Ventricular Function ,Left ,Blood Pressure Control and Regulation ,Clinical Trials ,Cardiorespiratory Medicine and Haematology ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology - Abstract
BackgroundHeart rate and systolic blood pressure (SBP) are prognostic markers in heart failure (HF) with reduced ejection fraction (HFrEF). Their combination in rate pressure product (RPP) as well as their role in heart failure with preserved ejection fraction (HFpEF) remains unclear.HypothesisRPP and its components are associated with HFpEF outcomes.MethodsWe performed an analysis of Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF; http://www.clinicaltrials.gov NCT00475852), which studied 7141 patients with acute HF. HFpEF was defined as left ventricular ejection fraction ≥40%. Outcomes were assessed by baseline heart rate, SBP, and RPP, as well as the change of these variables using adjusted Cox models.ResultsAfter multivariable adjustment, in-hospital change but not baseline heart rate, SBP, and RPP were associated with 30-day mortality/HF hospitalization (hazard ratio [HR]: 1.17 per 5-bpm heart rate, HR: 1.20 per 10-mm Hg SBP, and HR: 1.02 per 100 bpm × mm Hg RPP; all P
- Published
- 2018
34. Home-Time After Discharge Among Patients Hospitalized With Heart Failure
- Author
-
Greene, Stephen J, O’Brien, Emily C, Mentz, Robert J, Luo, Nancy, Hardy, N Chantelle, Laskey, Warren K, Heidenreich, Paul A, Chang, Chun-Lan, Turner, Stuart J, Yancy, Clyde W, Hernandez, Adrian F, Curtis, Lesley H, Peterson, Pamela N, Fonarow, Gregg C, and Hammill, Bradley G
- Subjects
Clinical Research ,Heart Disease ,Cardiovascular ,Aging ,Good Health and Well Being ,Aged ,Aged ,80 and over ,Cohort Studies ,Female ,Follow-Up Studies ,Heart Failure ,Hospitalization ,Humans ,Male ,Patient Discharge ,Prospective Studies ,Registries ,Self Care ,heart failure ,hospitalization ,outcomes ,patient-centered ,post-discharge ,Cardiorespiratory Medicine and Haematology ,Public Health and Health Services ,Cardiovascular System & Hematology - Abstract
BackgroundSurveys of patients with cardiovascular disease have suggested that "home-time"-being alive and out of any health care institution-is a prioritized outcome. This novel measure has not been studied among patients with heart failure (HF).ObjectivesThis study sought to characterize home-time following hospitalization for HF and assess its relationship with patient characteristics and traditionally reported clinical outcomes.MethodsUsing GWTG-HF (Get With The Guidelines-Heart Failure) registry data, patients discharged alive from an HF hospitalization between 2011 and 2014 and ≥65 years of age were identified. Using Medicare claims, post-discharge home-time over 30-day and 1-year follow-up was calculated for each patient as the number of days alive and spent outside of a hospital, skilled nursing facility (SNF), or rehabilitation facility.ResultsAmong 59,736 patients, 57,992 (97.1%) and 42,153 (70.6%) had complete follow-up for home-time calculation through 30 days and 1 year, respectively. The mean home-time was 21.6 ± 11.7 days at 30 days and 243.9 ± 137.6 days at 1 year. Contributions to reduced home-time varied by follow-up period, with days spent in SNF being the largest contributor though 30 days and death being the largest contributor through 1 year. Over 1 year, 2,044 (4.8%) patients had no home-time following index hospitalization discharge, whereas 8,194 (19.4%) had 365 days of home-time. In regression models, several conditions were associated with substantially reduced home-time, including chronic obstructive pulmonary disease, renal insufficiency, and dementia. Through 1 year, home-time was highly correlated with time-to-event endpoints of death (tau = 0.72) and the composite of death or HF readmission (tau = 0.59).ConclusionsHome-time, which can be readily calculated from administrative claims data, is substantially reduced for many patients following hospitalization for HF and is highly correlated with traditional time-to-event mortality and hospitalization outcomes. Home-time represents a novel, easily measured, patient-centered endpoint that may reflect effectiveness of interventions in future HF studies.
- Published
- 2018
35. Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure Insights From ASCEND-HF Trial
- Author
-
Cerbin, Lukasz P, Ambrosy, Andrew P, Greene, Stephen J, Armstrong, Paul W, Butler, Javed, Coles, Adrian, DeVore, Adam D, Ezekowitz, Justin A, Hernandez, Adrian F, Metra, Marco, Starling, Randall C, Tang, Wilson, Teerlink, John R, Voors, Adriaan A, Wu, Angie, O’Connor, Christopher M, and Mentz, Robert J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Clinical Research ,Cardiovascular ,Good Health and Well Being ,Acute Disease ,After-Hours Care ,Aged ,Dyspnea ,Emergency Service ,Hospital ,Female ,Heart Failure ,Humans ,Male ,Middle Aged ,Mortality ,Nitroglycerin ,Patient Readmission ,Posture ,Prognosis ,Proportional Hazards Models ,Respiratory Sounds ,Sodium Potassium Chloride Symporter Inhibitors ,Time Factors ,Vasodilator Agents ,heart failure ,presentation ,ASCEND-HF ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
OBJECTIVES:As the largest acute heart failure (AHF) trial conducted to date, the global ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial database presented an opportunity to systematically describe the relationship among time of hospital presentation, clinical profile, inpatient management, and outcomes among patients admitted with AHF. BACKGROUND:Time of hospital presentation has been shown to impact outcomes among patients hospitalized with many conditions. However, the association among time of presentation and patient characteristics, management, and clinical outcomes among patients hospitalized with AHF has not been well characterized. METHODS:A post hoc analysis of the ASCEND-HF trial was performed, which enrolled 7,141 patients hospitalized for AHF. Patients were divided based on when they presented to the hospital; regular hours were defined as 9 am to 5 pm, Monday through Friday, and off hours were defined as 5 pm to 9 am, Monday through Friday and weekends. Clinical characteristics and outcomes were compared by time of presentation. RESULTS:Overall, 3,298 patients (46%) presented during off hours. Off-hour patients were more likely to have orthopnea (80% vs. 74%, respectively) and rales (56% vs. 49%, respectively) than regular-hour patients. Off-hour patients were more likely to receive intravenous (IV) nitroglycerin (18% vs. 11%, respectively) and IV loop diuretics (92% vs. 86%, respectively) as initial therapy and reported greater relief from dyspnea at 24 h (odds ratio [OR]: 1.14; 95% confidence interval [CI]: 1.04 to 1.24; p = 0.01) than regular-hour patients. After adjustment, off-hour presentation was associated with significantly lower 30-day mortality (OR: 0.74; 95% CI: 0.57 to 0.96; p = 0.03) and 180-day mortality (hazard ratio [HR]: 0.82; 95% CI: 0.72 to 0.94; p = 0.01) but similar 30-day rehospitalization rates (p = 0.40). CONCLUSIONS:In this AHF trial, patients admitted during off hours exhibited a distinct clinical profile, experienced greater dyspnea relief, and had lower post-discharge mortality than regular-hour patients. These findings have implications for future AHF trials.
- Published
- 2018
36. Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
- Author
-
Carnicelli, Anthony P., Li, Zhen, Greiner, Melissa A., Lippmann, Steven J., Greene, Stephen J., Mentz, Robert J., Hardy, N. Chantelle, Blumer, Vanessa, Shen, Xian, Yancy, Clyde W., Peterson, Pamela N., Allen, Larry A., Fonarow, Gregg C., and O’Brien, Emily C.
- Published
- 2021
- Full Text
- View/download PDF
37. On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF
- Author
-
Kittipibul, Veraprapas, primary, Mentz, Robert J., additional, Clare, Robert M., additional, Wojdyla, Daniel M., additional, Anstrom, Kevin J., additional, Eisenstein, Eric L., additional, Ambrosy, Andrew P., additional, Goyal, Parag, additional, Skopicki, Hal A., additional, Ketema, Fassil, additional, Kim, Dong‐Yun, additional, Desvigne‐Nickens, Patrice, additional, Pitt, Bertram, additional, Velazquez, Eric J., additional, and Greene, Stephen J., additional
- Published
- 2024
- Full Text
- View/download PDF
38. Critical re‐evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure
- Author
-
Packer, Milton, primary, Anker, Stefan D., additional, Butler, Javed, additional, Cleland, John G.F., additional, Kalra, Paul R., additional, Mentz, Robert J., additional, Ponikowski, Piotr, additional, and Talha, Khawaja M., additional
- Published
- 2024
- Full Text
- View/download PDF
39. Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC
- Author
-
Mullens, Wilfried, primary, Damman, Kevin, additional, Dhont, Sebastiaan, additional, Banerjee, Debasish, additional, Bayes‐Genis, Antoni, additional, Cannata, Antonio, additional, Chioncel, Ovidiu, additional, Cikes, Maja, additional, Ezekowitz, Justin, additional, Flammer, Andreas J., additional, Martens, Pieter, additional, Mebazaa, Alexandre, additional, Mentz, Robert J., additional, Miró, Òscar, additional, Moura, Brenda, additional, Nunez, Julio, additional, Ter Maaten, Jozine M., additional, Testani, Jeffrey, additional, van Kimmenade, Roland, additional, Verbrugge, Frederik H., additional, Metra, Marco, additional, Rosano, Giuseppe M.C., additional, and Filippatos, Gerasimos, additional
- Published
- 2024
- Full Text
- View/download PDF
40. Patient Risk–Benefit Preferences for Transcatheter Versus Surgical Mitral Valve Repair
- Author
-
Hung, Anna, primary, Yang, Jui‐Chen, additional, Wallace, Matthew, additional, Zwischenberger, Brittany A., additional, Vemulapalli, Sreekanth, additional, Mentz, Robert J., additional, Thoma, Elizabeth, additional, Goates, Scott, additional, Lewis, John, additional, Strong, Susan, additional, and Reed, Shelby D., additional
- Published
- 2024
- Full Text
- View/download PDF
41. Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction
- Author
-
Salah, Husam M., Pandey, Ambarish, Soloveva, Anzhela, Abdelmalek, Manal F., Diehl, Anna Mae, Moylan, Cynthia A., Wegermann, Kara, Rao, Vishal N., Hernandez, Adrian F., Tedford, Ryan J., Parikh, Kishan S., Mentz, Robert J., McGarrah, Robert W., and Fudim, Marat
- Published
- 2021
- Full Text
- View/download PDF
42. Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction
- Author
-
Mentz, Robert J., Whellan, David J., Reeves, Gordon R., Pastva, Amy M., Duncan, Pamela, Upadhya, Bharathi, Nelson, M. Benjamin, Chen, Haiying, Reed, Shelby D., Rosenberg, Paul B., Bertoni, Alain G., O’Connor, Christopher M., and Kitzman, Dalane W.
- Published
- 2021
- Full Text
- View/download PDF
43. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
- Author
-
Schwartz, Gregory G., Gabriel Steg, P.h., Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Harrington, Robert A., Jukema, J. Wouter, Szarek, Michael, White, Harvey D., Zeiher, Andreas M., Tricoci, Pierluigi, Roe, Matthew T., Mahaffey, Kenneth W., Edelberg, Jay M., Hanotin, Corinne, Lecorps, Guillaume, Moryusef, Angèle, Pordy, Robert, Sasiela, William J., Tamby, Jean-François, Aylward, Philip E., Drexel, Heinz, Sinnaeve, Peter, Dilic, Mirza, Lopes, Renato D., Gotcheva, Nina N., Prieto, Juan-Carlos, Yong, Huo, López-Jaramillo, Patricio, Pećin, Ivan, Reiner, Zeljko, Ostadal, Petr, Poulsen, Steen Hvitfeldt, Viigimaa, Margus, Nieminen, Markku S., Danchin, Nicolas, Chumburidze, Vakhtang, Marx, Nikolaus, Liberopoulos, Evangelos, Montenegro Valdovinos, Pablo Carlos, Tse, Hung-Fat, Kiss, Robert Gabor, Xavier, Denis, Zahger, Doron, Valgimigli, Marco, Kimura, Takeshi, Kim, Hyo Soo, Kim, Sang-Hyun, Erglis, Andrejs, Laucevicius, Aleksandras, Kedev, Sasko, Yusoff, Khalid, Ramos López, Gabriel Arturo, Alings, Marco, Halvorsen, Sigrun, Correa Flores, Roger M., Sy, Rody G., Budaj, Andrzej, Morais, Joao, Dorobantu, Maria, Karpov, Yuri, Ristic, Arsen D., Chua, Terrance, Murin, Jan, Fras, Zlatko, Dalby, Anthony J., Tuñón, José, Asita de Silva, H., Hagström, Emil, Landmesser, Ulf, Müller, Christian, Chiang, Chern-En, Sritara, Piyamitr, Guneri, Sema, Parkhomenko, Alexander, Ray, Kausik K., Moriarty, Patrick M., Vogel, Robert, Chaitman, Bernard, Kelsey, Sheryl F., Olsson, Anders G., Rouleau, Jean-Lucien, Simoons, Maarten L., Alexander, Karen, Meloni, Chiara, Rosenson, Robert, Sijbrands, Eric J.G., Alexander, John H., Armaganijan, Luciana, Bagai, Akshay, Bahit, Maria Cecilia, Brennan, J. Matthew, Clifton, Shaun, DeVore, Adam D., Deloatch, Shalonda, Dickey, Sheila, Dombrowski, Keith, Ducrocq, Grégory, Eapen, Zubin, Endsley, Patricia, Eppinger, Arleen, Harrison, Robert W., Hess, Connie Ng, Hlatky, Mark A., Jordan, Joseph Dedrick, Knowles, Joshua W., Kolls, Bradley J., Kong, David F., Leonardi, Sergio, Lillis, Linda, Maron, David J., Marcus, Jill, Mathews, Robin, Mehta, Rajendra H., Mentz, Robert J., Moreira, Humberto Graner, Patel, Chetan B., Pereira, Sabrina Bernardez, Perkins, Lynn, Povsic, Thomas J., Puymirat, Etienne, Jones, William Schuyler, Shah, Bimal R., Sherwood, Matthew W., Stringfellow, Kenya, Sujjavanich, Darin, Toma, Mustafa, Trotter, Charlene, van Diepen, Sean F.P., Wilson, Matthew D., Tze-Kay Yan, Andrew, Schiavi, Lilia B., Garrido, Marcelo, Alvarisqueta, Andrés F., Sassone, Sonia A., Bordonava, Anselmo P., Alves De Lima, Alberto E., Schmidberg, Jorge M., Duronto, Ernesto A., Caruso, Orlando C., Novaretto, Leonardo P., Hominal, Miguel Angel, Montaña, Oscar R., Caccavo, Alberto, Gomez Vilamajo, Oscar A., Lorenzatti, Alberto J., Cartasegna, Luis R., Paterlini, Gustavo A., Mackinnon, Ignacio J., Caime, Guillermo D., Amuchastegui, Marcos, Salomone, Oscar, Codutti, Oscar R., Jure, Horacio O., Bono, Julio O.E., Hrabar, Adrian D., Vallejos, Julio A., Ahuad Guerrero, Rodolfo A., Novoa, Federico, Patocchi, Cristian A., Zaidman, Cesar J., Giuliano, Maria E., Dran, Ricardo D., Vico, Marisa L., Carnero, Gabriela S., Guzman, Pablo N., Medrano Allende, Juan C., Garcia Brasca, Daniela F., Bustamante Labarta, Miguel H., Nani, Sebastian, Blumberg, Eduardo D.S., Colombo, Hugo R., Liberman, Alberto, Fuentealba, Victorino, Luciardi, Hector L., Waisman, Gabriel D., Berli, Mario A., Garcia Duran, Ruben O., Cestari, Horacio G., Luquez, Hugo A., Giordano, Jorge A., Saavedra, Silvia S., Zapata, Gerardo, Costamagna, Osvaldo, Llois, Susana, Waites, Jonathon H., Collins, Nicholas, Soward, Allan, Hii, Chris L.S., Shaw, James, Arstall, Margaret A., Horowitz, John, Ninio, Daniel, Rogers, James F., Colquhoun, David, Oqueli Flores, Romulo E., Roberts-Thomson, Philip, Raffel, Owen, Lehman, Sam J., Aroney, Constantine, Coverdale, Steven G.M., Garrahy, Paul J., Starmer, Gregory, Sader, Mark, Carroll, Patrick A., Dick, Ronald, Zweiker, Robert, Hoppe, Uta, Huber, Kurt, Berger, Rudolf, Delle-Karth, Georg, Frey, Bernhard, Faes, Dirk, Hermans, Kurt, Pirenne, Bruno, Leone, Attilio, Hoffer, Etienne, Vrolix, Mathias C.M., De Wolf, Luc, Wollaert, Bart, Castadot, Marc, Dujardin, Karl, Beauloye, Christophe, Vervoort, Geert, Striekwold, Harry, Convens, Carl, Roosen, John, Barbato, Emanuele, Claeys, Marc, Cools, Frank, Terzic, Ibrahim, Barakovic, Fahir, Midzic, Zlatko, Pojskic, Belma, Fazlibegovic, Emir, Durak-Nalbantic, Azra, Kulić, Mehmed, Vulic, Dusko, Muslibegovic, Adis, Goronja, Boris, Reis, Gilmar, Sousa, Luciano, Nicolau, Jose C., Giorgeto, Flavio E., Silva, Ricardo P., Maia, Lilia Nigro, Rech, Rafael, Rossi, Paulo R.F., Cerqueira, Maria José A.G., Duda, Norberto, Kalil, Renato, Kormann, Adrian, Abrantes, José Antonio M., Filho, Pedro Pimentel, Soggia, Ana Priscila, de Santos, Mayler O.N., Neuenschwander, Fernando, Bodanese, Luiz C., Michalaros, Yorghos L., Eliaschewitz, Freddy G., Vidotti, Maria H., Leaes, Paulo E., Botelho, Roberto V., Kaiser, Sergio, Fernandes Manenti, Euler Roberto F., Precoma, Dalton B., Moura Jorge, Jose C., Silva, Pedro, Silveira, Jose A., Saporito, Wladmir, Marin Neto, Jose A., Feitosa, Gilson S., Ritt, Luiz Eduardo F., de Souza, Juliana A., Costa, Fernando, Souza, Weimar K.S.B., Reis, Helder J.L., Machado, Leandro, Aidar Ayoub, José Carlos, Todorov, Georgi V., Nikolov, Fedya P., Velcheva, Elena S., Tzekova, Maria L., Benov, Haralambi O., Petranov, Stanislav L., Tumbev, Haralin S., Shehova-Yankova, Nina S., Markov, Dimitar T., Raev, Dimitar H., Mollov, Mihail N., Kichukov, Kostadin N., Ilieva-Pandeva, Katya A., Ivanova, Raya, Gospodinov, Maryana, Mincheva, Valentina M., Lazov, Petar V., Dimov, Bojidar I., Senaratne, Manohara, Stone, James, Kornder, Jan, Pearce, Stephen, Dion, Danielle, Savard, Daniel, Pesant, Yves, Pandey, Amritanshu, Robinson, Simon, Gosselin, Gilbert, Vizel, Saul, Hoag, Gordon, Bourgeois, Ronald, Morisset, Anne, Sabbah, Eric, Sussex, Bruce, Kouz, Simon, MacDonald, Paul, Diaz, Ariel, Michaud, Nicolas, Fell, David, Leung, Raymond, Vuurmans, Tycho, Lai, Christopher, Nigro, Frank, Davies, Richard, Nogareda, Gustavo, Vijayaraghavan, Ram, Ducas, John, Lepage, Serge, Mehta, Shamir, Cha, James, Dupuis, Robert, Fong, Peter, Lutchmedial, Sohrab, Rodes-Cabau, Josep, Fadlallah, Hussein, Cleveland, David, Huynh, Thao, Bata, Iqbal, Hameed, Adnan, Pincetti, Cristian, Potthoff, Sergio, Prieto, Juan C., Acevedo, Monica, Aguirre, Arnoldo, Vejar, Margarita, Yañez, Mario, Araneda, Guillermo, Fernandez, Mauricio, Perez, Luis, Varleta, Paola, Florenzano, Fernando, Huidobro, Laura, Raffo, Carlos A., Olivares, Claudia, Nahuelpan, Leonardo, Montecinos, Humberto, Chen, Jiyan, Dong, Yugang, Huang, Weijian, Wang, Jianzhong, Huang, Shi'An, Yao, Zhuhua, Li, Xiang, Cui, Lan, Lin, Wenhua, Sun, Yuemin, Wang, Jingfeng, Li, Jianping, Zhang, Xuelian, Zhu, Hong, Chen, Dandan, Huang, Lan, Dong, Shaohong, Su, Guohai, Xu, Biao, Su, Xi, Cheng, Xiaoshu, Lin, Jinxiu, Zong, Wenxia, Li, Huanming, Feng, Yi, Xu, Dingli, Yang, Xinchun, Ke, Yuannan, Lin, Xuefeng, Zhang, Zheng, Zheng, Zeqi, Luo, Zhurong, Chen, Yundai, Ding, Chunhua, Zhong, Yi, Zheng, Yang, Li, Xiaodong, Peng, Daoquan, Zhao, Shuiping, Li, Ying, Liu, Xuebo, Wei, Meng, Liu, Shaowen, Yu, Yihua, Qu, Baiming, Jiang, Weihong, Zhou, Yujie, Zhao, Xingsheng, Yuan, Zuyi, Guo, Ying, Xu, Xiping, Shi, Xubo, Ge, Junbo, Fu, Guosheng, Bai, Feng, Fang, Weiyi, Shou, Xiling, Yang, Xiangjun, Wang, Jian'An, Xiang, Meixiang, Sun, Yingxian, Lu, Qinghua, Zhang, Ruiyan, Zhu, Jianhua, Xu, Yizhou, Fan, Zhongcai, Li, Tianchang, Wu, Chun, Jaramillo, Nicolas, Vallejo, Gregorio Sanchez, Luna Botia, Diana C., Lopez, Rodrigo Botero, Molina De Salazar, Dora I., Cadena Bonfanti, Alberto J., Aroca, Carlos Cotes, Higuera, Juan Diego, Blanquicett, Marco, Barrera Silva, Sandra I., Garcia Lozada, Henry J., Coronel Arroyo, Julian A., Accini Mendoza, Jose L., Fernandez Ruiz, Ricardo L., Quintero Ossa, Alvaro M., Manzur Jatin, Fernando G., Herazo, Aristides Sotomayor, Parada, Jeffrey Castellanos, Arambula, Rafael Suarez, Urina Triana, Miguel A., Fernandez Trujillo, Angela M., Strozzi, Maja, Car, Siniša, Jerić, Melita, Miličić, Davor, Benčić, Martina Lovrić, Pintarić, Hrvoje, Prvulović, Đeiti, Šikić, Jozica, Peršić, Viktor, Mileta, Dean, Štambuk, Kresimir, Babić, Zdravko, Tomulic, Vjekoslav, Lukenda, Josip, Mejic-Krstulovic, Stanka, Starcevic, Boris, Spinar, Jindrich, Horak, David, Velicka, Zdenek, Stasek, Josef, Alan, David, Machova, Vilma, Linhart, Ales, Novotny, Vojtech, Kaucak, Vladimir, Rokyta, Richard, Naplava, Robert, Coufal, Zdenek, Adamkova, Vera, Podpera, Ivo, Zizka, Jiri, Motovska, Zuzana, Marusincova, Ivana, Svab, Premysl, Heinc, Petr, Kuchar, Jiri, Povolny, Petr, Matuska, Jiri, Poulsen, Steen H., Raungaard, Bent, Clemmensen, Peter, Bang, Lia E., May, Ole, Bøttcher, Morten, Hove, Jens D., Frost, Lars, Gislason, Gunnar, Larsen, John, Johansen, Peter Betton, Hald, Flemming, Johansen, Peter, Jeppesen, Jørgen, Nielsen, Tonny, Kristensen, Kjeld S., Walichiewicz, Piotr Maria, Lomholdt, Jens D., Klausen, Ib C., Nielsen, Peter Kaiser, Davidsen, Flemming, Videbaek, Lars, Soots, Mai, Vahula, Veiko, Hedman, Anu, Soopõld, Üllar, Märtsin, Kaja, Jurgenson, Tiina, Kristjan, Arved, Huikuri, Heikki, Pierre Coste, Juhani Airaksinen, Ferrari, Emile, Morel, Olivier, Montalescot, Gilles, Machecourt, Jacques, Barone-Rochette, Gilles, Mansourati, Jacques, Cottin, Yves, Leclercq, Florence, Belhassane, Abdelkader, Delarche, Nicolas, Boccara, Franck, Paganelli, Franck, Clerc, Jérôme, Schiele, Francois, Aboyans, Victor, Probst, Vincent, Berland, Jacques, Lefèvre, Thierry, Citron, Bernard, Khintibidze, Irakli, Shaburishvili, Tamaz, Pagava, Zurab, Ghlonti, Ramaz, Lominadze, Zaza, Khabeishvili, George, Hemetsberger, Rayyan, Edward, Kemala, Rauch-Kröhnert, Ursula, Stratmann, Matthias, Appel, Karl-Friedrich, Schmidt, Ekkehard, Omran, Heyder, Stellbrink, Christoph, Dorsel, Thomas, Lianopoulos, Emmanouil, Vöhringer, Hans Friedrich, Marx, Roger, Zirlik, Andreas, Schellenberg, Detlev, Heitzer, Thomas, Laufs, Ulrich, Werner, Christian, Gielen, Stephan, Nuding, Sebastian, Winkelmann, Bernhard, Behrens, Steffen, Sydow, Karsten, Karakas, Mahir, Simonis, Gregor, Muenzel, Thomas, Werner, Nikos, Leggewie, Stefan, Böcker, Dirk, Braun-Dullaeus, Rüdiger, Toursarkissian, Nicole, Jeserich, Michael, Weißbrodt, Matthias, Schaeufele, Tim, Weil, Joachim, Völler, Heinz, Waltenberger, Johannes, Natour, Mohammed, Schmitt, Susanne, Müller-Wieland, Dirk, Steiner, Stephan, Heidenreich, Lothar, Offers, Elmar, Gremmler, Uwe, Killat, Holger, Rieker, Werner, Patsilinakos, Sotiris, Kartalis, Athanasios, Manolis, Athanassios, Sionis, Dimitrios, Chachalis, Geargios, Skoumas, Ioannis, Athyros, Vasilios, Vardas, Panagiotis, Parthenakis, Frangkiskos, Lekakis, John, Hatzitolios, Apostolos, Fausto Ovando, Sergio R., Arango Benecke, Juan L., Rodriguez De Leon, Edgar R., Yan, Bryan P.Y., Siu, David C.W., Turi, Tibor, Merkely, Bela, Ungi, Imre, Lupkovics, Geza, Nagy, Lajos, Katona, András, Édes, István, Müller, Gábor, Horvath, Iván, Kapin, Tibor, Szigeti, Zsolt, Faluközy, József, Kumbla, Mukund, Sandhu, Manjinder, Annam, Sharath, Proddutur, Naveen Reddy, Regella, Reddy, Premchand, Rajendra K., Mahajan, Ajaykumar, Pawar, Sudhir, Abhyanakar, Atul D., Kerkar, Prafulla, Govinda, Ravishankar A., Oomman, Abraham, Sinha, Dhurjati, Patil, Sachin N., Kahali, Dhiman, Sawhney, Jitendra, Joshi, Abhijeet B., Chaudhary, Sanjeev, Harkut, Pankaj, Guha, Santanu, Porwal, Sanjay, Jujjuru, Srimannarayana, Pothineni, Ramesh B., Monteiro, Minguel R., Khan, Aziz, Iyengar, Shamanna S., Grewal, Jasprakash Singh, Chopda, Manoj, Fulwani, Mahesh C., Patange, Aparna, Sachin, Patil, Chopra, Vijay K., Goyal, Naresh K., Shinde, Rituparna, Manakshe, Gajendra V., Patki, Nitin, Sethi, Sumeet, Munusamy, Vengatesh, Sunil Thanvi, Sunil Karnaand, Adhyapak, Srilakshmi, Patil, Chandrakant, Pandurangi, Ulhas, Mathur, Rishabh, Gupta, Jugal, Kalashetti, Suhas, Bhagwat, Ajit, Raghuraman, Bagirath, Yerra, Shiv Kumar, Bhansali, Prasant, Borse, Rohidas, Rahul, Patil, Das, Srihari, Kumar, Vinay, Abdullakutty, Jabir, Saathe, Shireesh, Palimkar, Priya, Abdullkutty, Jabir, Sathe, Shireesh, Atar, Shaul, Shechter, Michael, Mosseri, Morris, Arbel, Yaron, Ehud, Chorin, Ofer, Havakuk, Lotan, Chaim, Rosenschein, Uri, Katz, Amos, Henkin, Yaakov, Francis, Adi, Klutstein, Marc, Nikolsky, Eugenia, Zukermann, Robert, Turgeman, Yoav, Halabi, Majdi, Marmor, Alon, Kornowski, Ran, Jonas, Michael, Amir, Offer, Hasin, Yonathan, Rozenman, Yoseph, Fuchs, Shmuel, Zvi, Vered, Hussein, Osamah, Gavish, Dov, Vered, Zvi, Caraco, Yoseph, Elias, Mazen, Tov, Naveh, Wolfovitz, Efrat, Lishner, Michael, Elias, Nizar, Piovaccari, Giancarlo, De Pellegrin, Annamaria, Garbelotto, Raffaella, Guardigli, Gabriele, Marco, Valgimigli, Licciardello, Giovanni, Auguadro, Carla, Scalise, Filippo, Cuccia, Claudio, Salvioni, Alessandro, Musumeci, Giuseppe, Senni, Michelle, Calabrò, Paolo, Novo, Salvatore, Faggiano, Pompilio, Metra, Marco, De Cesare, Nicoletta B., Berti, Sergio, Cavallini, Claudio, Puccioni, Enrico, Galvani, Marcello, Tespili, Maurizio, Piatti, Piermarco, Palvarini, Michela, De Luca, Giuseppe, Violini, Roberto, De Leo, Alessandro, Olivari, Zoran, Filardi, Pasquale Perrone, Ferratini, Maurizio, Racca, Vittorio, Dai, Kazuoki, Shimatani, Yuji, Kamiya, Haruo, Ando, Kenji, Takeda, Yoshihiro, Morino, Yoshihiro, Hata, Yoshiki, Kimura, Kazuo, Kishi, Koichi, Michishita, Ichiro, Uehara, Hiroki, Higashikata, Toshinori, Hirayama, Atsushi, Hirooka, Keiji, Doi, Yasuji, Sakagami, Satoru, Taguchi, Shuichi, Koike, Akihiro, Fujinaga, Hiroyuki, Koba, Shinji, Kozuma, Ken, Kawasaki, Tomohiro, Ono, Yujiro, Shimizu, Masatoshi, Katsuda, Yousuke, Wada, Atsuyuki, Shinke, Toshiro, Ako, Junya, Fujii, Kenshi, Takahashi, Toshiyuki, Sakamoto, Tomohiro, Nakao, Koichi, Furukawa, Yutaka, Sugino, Hiroshi, Tamura, Ritsu, Mano, Toshiaki, Uematsu, Masaaki, Utsu, Noriaki, Ito, Kashima, Haraguchi, Takuya, Sato, Katsuhiko, Ueda, Yasunori, Nishibe, Akira, Fujimoto, Kazuteru, Masutani, Motomaru, Yoon, Jung Han, Kim, Hack-Lyoung, Park, Hun Sik, Chae, In-Ho, Kim, Moo Hyun, Jeong, Myung Ho, Rha, Seungwoon, Kim, Chongjin, Kim, Hae Young, Hong, Taekjong, Tahk, Seung-Jea, Kim, Youngkwon, Busmane, Arija, Pontaga, Natalija, Strelnieks, Aldis, Mintale, Iveta, Sime, Iveta, Petrulioniene, Zaneta, Kavaliauskiene, Roma, Jurgaitiene, Ruta, Sakalyte, Gintare, Slapikas, Rimvydas, Norkiene, Sigute, Misonis, Nerijus, Kibarskis, Aleksandras, Kubilius, Raimondas, Bojovski, Stojko, Lozance, Nensi, Kjovkaroski, Aleksandar, Doncovska, Snezana, Ong, Tiong Kiam, Kasim, Sazzli, Maskon, Oteh, Kandasamy, Balachandran, Liew, Houng B., Izani Wan Mohamed, Wan Mohd, Castillo, Armando García, Calvillo, Jorge Carrillo, Campos, Pedro Fajardo, Núñez Fragoso, Juan Carlos, Bayram Llamas, Edmundo Alfredo, Alcocer Gamba, Marco Antonio, Madrigal, Jaime Carranza, González Salas, Luis Gerardo, Rosas, Enrique López, González Díaz, Belinda, Salcido Vázquez, Eduardo, Nacoud Ackar, Alfredo, Antonio Llamas Esperón, Guillermo, Rodolfo Martínez Sánchez, Carlos, Guerrero De Leon, María, Suarez Otero, Rodrigo, Fanghänel Salmón, Guillermo, Pérez Ríos, Jesús Antonio, Garza Ruíz, José Angel, Breedveld, Robert W., Feenema-Aardema, Margriet, Borger-Van Der Burg, Alida, Hoogslag, Pieter A.M., Suryapranata, Harry, Oomen, Antonius, Van Haelst, Paulus, Feenema-Aradema, Margriet, Wiersma, Jacobijne J., Basart, Dirk, Van Der Wal, Ruud M.A., Zwart, Peter, Monraats, Pascalle, Van Kesteren, Henricus, Karalis, Ioannis, Jukema, Johan, Verdel, Gerardus J.E., Brueren, Bart R.G., Troquay, Roland PTh, Viergever, Eric P., Al-Windy, Nadea Y.Y., Bartels, Gerard L., Cornel, Jan H., Hermans, Walter R.M., Herrman, Johannes P.R., Bos, Robert J., Groutars, Reginald G.E.J., Van Der Zwaan, Coenraad C., Kaplan, Refik, Lionarons, Raymond, Ronner, Eelko, Groenemeijer, Bjorn E., Bronzwaer, Patrick N.A., Liem, Anho A.H., Rensing, Bernard J.W.M., Bokern, Marcel J.J.A., Nijmeijer, Remco, Hersbach, Ferry M.R.J., Willems, Frank F., Gosselink, Antonius T.M., Rasoul, Saman, Elliott, John, Wilkins, Gerard, Fisher, Raewyn, Scott, Douglas, Hart, Hamish, Stewart, Ralph, Harding, Scott, Ternouth, Ian, Fisher, Nicholas, Wilson, Samuel, Aitken, Denise, Anscombe, Russell, Davidson, Laura, Tomala, Tadeusz, Nygård, Ottar, Sparby, Jon Arne, Andersen, Kjell, Gullestad, Lars, Jortveit, Jarle, Munk, Peter S., Singsaas, Erlend gyllensten, Hurtig, Ulf, Calderon Ticona, Jorge R., Durand Velasquez, Julio R., Negron Miguel, Sandra A., Sanabria Perez, Enrique S., Carrion Chambilla, Jesus M., Chavez Ayala, Carlos A., Castillo Leon, Reynaldo P., Vargas Gonzales, Rolando J., Hernandez Zuniga, Jose D., Camacho Cosavalente, Luis A., Bravo Mannucci, Jorge E., Landeo, Javier Heredia, Llerena Navarro, Nassip C., Roldan Concha, Yudy M., Rodriguez Chavez, Víctor E., Anchante Hernandez, Henry A., Zea Nunez, Carlos A., Ramos, Walter Mogrovejo, Ferrolino, Arthur, Sy, Rosa Allyn G., Tirador, Louie, Matiga, Generoso, Coching, Raul Martin, Bernan, Alisa, Rogelio, Gregorio, Morales, Dante D., Tan, Edgar, Sulit, Dennis Jose, Wlodarczak, Adrian, Jaworska, Krystyna, Skonieczny, Grzegorz, Pawlowicz, Lidia, Wojewoda, Pawel, Busz-Papiez, Benita, Bednarski, Janusz, Goch, Aleksander, Staneta, Pawel, Dulak, Elzbieta, Saminski, Krzysztof, Krasowski, Wlodzimierz, Sudnik, Wanda, Zurakowski, Aleksander, Skorski, Marcin, Lysek, Roman, Miklaszewicz, Beata, Kubica, Jacek, Lipko, Jan Andrzej, Kostarska-Srokosz, Edyta, Piepiorka, Marek, Drzewiecka, Anna, Sciborski, Ryszard, Stasiewski, Arkadiusz, Blicharski, Tomasz, Bystryk, Leszek, Szpajer, Michal, Korol, Marek, Czerski, Tomasz, Mirek-Bryniarska, Ewa, Gniot, Jacek, Lubinski, Andrzej, Gorny, Jerzy, Franek, Edward, Raczak, Grzegorz, Szwed, Hanna, Monteiro, Pedro, Bastos, Jose Mesquita, Pereira, Helder H., Martins, Dinis, Seixo, Filipe, Mendonça, Carlos, Botelho, Ana, Caetano, Francisca, Minescu, Bogdan, Istratoaie, Octavian, Tesloianu, Dan N., Cristian, Gabriel, Dumitrescu, Silviu, Podoleanu, Cristian G.C., Constantinescu, Mircea C.A., Bengus, Cristina M., Militaru, Constantin, Rosu, Doina, Parepa, Irinel R., Matei, Adrian V., Alexandru, Tom M., Malis, Mihaela, Coman, Ioan, Stanescu-Cioranu, Rodica, Dimulescu, Doina, Shvarts, Yury, Orlikova, Olga, Kobalava, Zhanna, Barbarash, Olga L., Markov, Valentin, Lyamina, Nadezhda, Gordienko, Alexander, Zrazhevsky, Konstantin, Vishnevsky, Alexander Y., Gurevich, Victor, Stryuk, Raisa, Lomakin, Nikita V., Bokarev, Igor, Khlevchuk, Tatiana, Shalaev, Sergey, Khaisheva, Larisa, Chizhov, Petr, Viktorova, Inna, Osokina, Natalya, Shchekotov, Vladimir, Akatova, Evgenia, Chumakova, Galina, Libov, Igor, Voevoda, Mikhail I., Tretyakova, Tatyana V., Baranov, Evgeny, Shustov, Sergey, Yakushin, Sergey, Gordeev, Ivan, Khasanov, Niiaz, Reshetko, Olga, Sotnikova, Tatiana, Molchanova, Olga, Nikolaev, Konstantin, Gapon, Liudmila, Baranova, Elena, Shogenov, Zaur, Kosmachova, Elena, Karpov, Yuriy, Povzun, Anton, Egorova, Liudmila, Tyrenko, Vadim V., Ivanov, Igor G., Ilya, Masterov, Kanorsky, Sergey, Simic, Dragan, Ivanovic, Nikola, Davidovic, Goran, Tasic, Nebojsa, Asanin, Milika R., Stojic, Stevo, Apostolovic, Svetlana R., Ilic, Stevan, Tosic, Biljana Putnikovic, Stankovic, Aleksandar, Arandjelovic, Aleksandra, Radovanovic, Slavica, Todic, Branislava, Balinovac, Jovan, Dincic, Dragan V., Seferovic, Petar, Karadzic, Ana, Dodic, Slobodan, Dimkovic, Sinisa, Jakimov, Tamara, Poh, Kian-Keong, Ong, Hean Yee, I-Shing, Justin Tang, Micko, Karol, Nociar, Jan, Pella, Daniel, Fulop, Peter, Hranai, Marian, Palka, Juraj, Mazur, Juraj, Majercák, Ivan, Dzupina, Andrej, Fazekas, František, Gonsorcik, Jozef, Bugan, Viliam, Selecky, Juraj, Kamensky, Gabriel, Strbova, Jaroslava, Smik, Rudolf, Dukat, Andrej, Olexa, Peter, Žuran, Ivan, Poklukar, Janez, Šuligoj, Nataša Černič, Cevc, Matija, Cyster, Henry P., Ranjith, Naresh, Corbett, Clive, Bayat, Junaid, Makotoko, Ellen Makoali, du Toit Theron, Hendrik, Kapp, Ilse E., de V Basson, Matthys M., Lottering, Hanlie, Van Aswegen, Dina, Van Zyl, Louis J., Sebastian, Peter J., Pillay, Thayabran, Saaiman, Jan A., Commerford, Patrick J., Cassimjee, Soraya, Riaz, Garda, Ebrahim, Iftikhar O., Sarvan, Mahomed, Mynhardt, Joseph H., Reuter, Helmuth, Moodley, Rajendran, Vida, Manuel, Cequier Fillat, Angel R., Peris, Vicente Bodí, Jimenez, Francisco Fuentes, Marín, Francisco, Cruz Fernández, Jose M., Hidalgo Urbano, Rafael Jesus, Gil-Extremera, Blas, Toledo, Pablo, Diz, Fernando Worner, Garcia-Dorado, David, Iñiguez, Andres, Fernández, José Tuñón, Gonzalez-Juanatey, Jose R., Portales, Javier Fernandez, Murillo, Fernando Civeira, Pericas, Laia Matas, Zamorano, Jose Luis, De Mora Martin, Manuel, Cortada, Jordi Bruguera, Alonso Martin, Joaquin J., Serrano Antolin, Jose Maria, De Berrazueta Fernández, José R., Vázquez de Prada, José Antonio, Díaz Fernández, Jose Francisco, García Lledó, José Alberto, Sales, Juan Cosín, Rodriguez, Javier Botas, Tragant, Gabriel Gusi, Benedicto, Amparo, Gonzalez-Juanatey, Carlos, Potau, Mercedes Camprubí, Perez, Ignacio Plaza, De La Tassa, César Morís, Loma-Osorio Rincon, Pablo, Recena, Javier Balaguer, Escudier, Juan M., Payeras, Antonio Coca, Orcajo, Norberto Alonso, Valdivielso, Pedro, Constantine, Godwin, Haniffa, Ruvaiz, Tissera, Nirmali, Amarasekera, Stanley, Ponnamperuma, Chandrike, Fernando, Nimali, Fernando, Kaputella, Jayawardena, Jayanthimala, Wijeyasingam, Santharaj, Ranasinghe, Gotabhaya, Ekanayaka, Ruvan, Mendis, Sepalika, Senaratne, Vajira, Mayurathan, Gnanamoorthy, Rajapaksha, Ajantha, Sirisena, Thilak, Herath, Jagath I., Amarasena, Naomali, Berglund, Stefan, Rasmanis, Gundars, Vedin, Ola, Witt, Nils, Mourtzinis, Georgios, Nicol, Peter, Hansen, Ole, Romeo, Stefano, Jensen, Steen Agergaard, Torstensson, Ingemar, Ahremark, Ulf, Sundelin, Torbjörn, Moccetti, Tiziano, Mach, Francois, Binde, Ronald, Gämperli, Oliver, Tsai, Wei-Chuan, Ueng, Kwo-Chang, Lai, Wen-Ter, Liu, Ming-En, Hwang, Juey-Jen, Yin, Wei-Hsian, Hsieh, I-Chang, Hsieh, Ming-Jer, Lin, Wei Hsiang, Kuo, Jen-Yuan, Huang, Tsuei-Yuan, Fang, Chih-Yuan, Kaewsuwanna, Pinij, Soonfuang, Wasant, Jintapakorn, Woravut, Sukonthasarn, Apichard, Wongpraparut, Nattawut, Sastravaha, Krisada, Sansanayudh, Nakarin, Kehasukcharoen, Wirash, Piyayotai, Dilok, Chotnoparatpat, Paiboon, Camsari, Ahmet, Kultursay, Hakan, Mutlu, Bulent, Ersanli, Murat, Demirtas, Mustafa, Kirma, Cevat, Ural, Ertan, Koldas, Lale, Karpenko, Oleksandr, Prokhorov, Alexander, Vakaluyk, Ihor, Myshanych, Halyna, Reshotko, Dmytro, Batushkin, Valeriy, Rudenko, Leonid, Kovalskyi, Ihor, Kushnir, Mykola, Tseluyko, Vira, Mostovoy, Yuriy, Stanislavchuk, Mykola, Kyiak, Yulian, Karpenko, Yuriy, Malynovsky, Yaroslav, Klantsa, Andriy, Kutniy, Oles, Amosova, Ekaterina, Tashchuk, Viktor, Leshchuk, Oleh, Rishko, Mykola, Kopytsya, Mykola, Yagensky, Andriy, Vatutin, Mykola, Bagriy, Andriy, Barna, Olga M., Ushakov, Olexiy, Dzyak, Georgiy, Goloborodko, Borys, Rudenko, Anatolii, Zheleznyy, Volodymyr, Trevelyan, Jasper, Zaman, Azfar, Lee, Kaeng, Moriarty, Andrew, Aggarwal, Rajesh K., Clifford, Piers, Wong, Yuk-Ki, Iqbal, Syed M.R., Subkovas, Eduardas, Braganza, Denise, Sarkar, David, Storey, Robert, Griffiths, Huw, Mcclure, Sam, Muthusamy, Rangasamy, Smith, Simon, Kurian, John, Levy, Terry, Barr, Craig, Kadr, Honer, Gerber, Robert, Simaitis, Audrius, Soran, Handrean, Mathur, Anthony, Brodison, Adrian, Ayaz, Mohammad, Cheema, Muhammad, Oliver, Richard, Thackray, Simon, Mudawi, Telal, Rahman, Gohar, Sultan, Ayyaz, Reynolds, Timothy, Sharman, David, david Sprigings, Butler, Rob, Wilkinson, Peter, Lip, Gregory Y.H., Halcox, Julian, Gallagher, Sean, Ossei-Gerning, Nicholas, Vardi, Gil, Baldari, Duccio, Brabham, David, Treasure, Charles, II, Dahl, Charles, Palmer, Bruce, Wiseman, Alan, Khan, Abul, Puri, Sanjeev, Mohart, Ann Elizabeth, Ince, Carlos, Flores, Enrique, Wright, Scott, Cheng, Shi-Chi, Rosenberg, Michael, Rogers, William, Jr., Kosinski, Edward, Forgosh, Les, Waltman, Jonathan, Khan, Misal, Shoukfeh, Mohammad, Dagher, Georges, Cambier, Patrick, Lieber, Ira, Kumar, Priya, East, Cara, Krichmar, Perry, Hasan, Mian, White, Lindsey, Knickelbine, Thomas, Haldis, Thomas, Gillespie, Eve, Amidon, Thomas, Suh, David, Arif, Imran, Abdallah, Mouhamad, Akhter, Faiq, Carlson, Eric, D'Urso, Michael, El-Ahdab, Fadi, Nelson, William, Moriarty, Katie, Harris, Barry, Cohen, Steven, Carter, Luther, Doty, Daniel, Sabatino, Kenneth, Haddad, Tariq, Malik, Amir, Rao, Sunder, Mulkay, Angel, Jovin, Ion, Klancke, Kim, Malhotra, Vinay, Devarapalli, Sai K., Koren, Michael, Chandna, Harish, Dodds, George, III, Goraya, Tauqir, Bengston, James, Janik, Matthew, Moran, Joseph, Sumner, Andrew, Kobayashi, John, Davis, William, Yazdani, Shahram, Pasquini, John, Thakkar, Maitreya, Vedere, Amarnath, Leimbach, Wayne, Rider, James, fenton, Sarah, Singh, Narendra, Shah, Anil V., Janosik, Denise, Pepine, Carl, Berman, Brett, Gelormini, Joseph, Daniels, Christopher, Richard, Kerensky, Keating, Friederike, Kondo, Nicholas I., Shetty, Sanjay, Levite, Howard, Waider, Winfried, Takata, Theodore, Abu-Fadel, Mazen, Shah, Vipul, Aggarwal, Rahul, Izzo, Mark, Kumar, Anil, Hattler, Brack, Do, Rose, Link, Chad, Bortnick, Anna, Kinzfogl, George, III, Ghitis, Arnold, Larry, John, Teufel, Edward, Kuhlman, Peter, Mclaurin, Brent, Zhang, Wenwu, Thew, Stephen, Abbas, Jalal, White, Matthew, Islam, Othman, Subherwal, Sumeet, Ranadive, Nandkishore, Vakili, Babak, Gring, Christian, Henderson, David, Schuchard, Timothy, Farhat, Naim, Kline, Geoffrey, Mahal, Sharan, Whitaker, Jack, Speirs, Shawn, Andersen, Rolf, Daboul, Nizar, Horwitz, Phillip, Zahr, Firas, Ponce, George, Jafar, Zubair, Mcgarvey, Joseph, Jr., Panchal, Vipul, Voyce, Stephen, Blok, Thomas, Sheldon, William, Azizad, Masoud M., Schmalfuss, Carsten, Picone, Mark, Pederson, Robert, Herzog, William, Jr., Friedman, Keith, Lindsey, Jason, Nowins, Rosemary, Timothy, Eichenlaub, Leonard, Parilak, Lepor, Norman, El Shahawy, Mahfouz, Weintraub, Howard, Irimpen, Anand, Alonso, Alvaro, May, Wade, Christopher, Daniels, Galski, Thomas, Chu, Alan, Mody, Freny, Ramin, Ebrahimi, Hodes, Zachary, Rossi, Joseph, Rose, Gregory, Fairlamb, James, Lambert, Charles, Jr., Raisinghani, Ajit, Abbate, Antonio, Vetrovec, George, King, Marilyn, Carey, Charles, Gerber, Jaime, Younis, Liwa, Park, Hyeun, Vidovich, Mladen, Knutson, Thomas, Friedman, Dennis, Chaleff, Fred, Loussararian, Arthur, Rozeman, Phillip, Kimmelstiel, Carey, Kuvin, Jeffrey, Silver, Kevin, Foster, Malcolm, Tonnessen, Glen, Espinoza, Andrey, Amlani, Mohamadali, Wali, Andreas, Malozzi, Christopher, Jong, Geert T., Massey, Clara, Wattanakit, Keattiyoat, O'Donnell, Philip J., Singal, Dinesh, Jaffrani, Naseem, Banuru, Sridhar, Fisher, Daniel, Xenakis, Mark, Perlmutter, Neal, Bhagwat, Ravi, Strader, James, Jr., Blonder, Ronald, Akyea-Djamson, Ayim, Labroo, Ajay, Lee, Kwan, Marais, H. John, Claxton, Edmund, Jr., Weiss, Robert, Kathryn, Rohr, Berk, Martin, Rossi, Peter, Joshi, Parag, Khera, Amit, Khaira, Ajit S., Kumkumian, Greg, Lupovitch, Steven, Purow, Joshua, Welka, Stephen, Hoffman, David, Fischer, Stuart, Soroka, Eugene, Eagerton, Donald, Pancholy, Samir, Ray, Michael, Erenrich, Norman, Farrar, Michael, Pollock, Stewart, French, William J., Diamantis, Steve, Guy, Douglas, Gimple, Lawrence, Neustel, Mark, Schwartz, Steven, Pereira, Edward, Albert, Seals, Spriggs, Douglas, Strain, Janet, Mittal, Suneet, Vo, Anthony, Chane, Majed, Hall, Jason, Vijay, Nampalli, Lotun, Kapildeo, Lester, F. Martin, Nahhas, Ahed, Pope, Theodore, Nager, Paul, Vohra, Rakesh, Sharma, Mukesh, Bashir, Riyaz, Ahmed, Hinan, Berlowitz, Michael, Fishberg, Robert, Barrucco, Robert, Yang, Eric, Radin, Michael, Sporn, Daniel, Stapleton, Dwight, Eisenberg, Steven, Landzberg, Joel, Mcgough, Martin, Turk, Samir, Schwartz, Michael, Sundram, P. Sandy, Jain, Diwakar, Zainea, Mark, Bayron, Carlos, Karlsberg, Ronald, Dohad, Suhail, Lui, Henry, Keen, William, Westerhausen, Donald, Jr., Khurana, Sandeep, Agarwal, Himanshu, Birchem, Jessica, Penny, William, Jr., Chang, Mark, Murphy, Sherrill, Henry, John, Schifferdecker ;John M Gilbert, Branislav, Chalavarya, Gopal, Eaton, Charles, Schmedtje, John F., Jr., Christenson, Stuart, Dotani, Imran, Denham, Douglas, Macdonell, Alexander, Gibson, Paul, Rahman, Aref, Al Joundi, Tammam, Assi, Nizar, Conrad, Gary, Kotha, Purushotham, Love, Michael, Giesler, Gregory, Rubenstein, Howard, Gamil, Dawood, Akright, Laura, Krawczyk, Justine, Cobler, Joanne, Wells, Terry, Welker, James, Foster, Robert, Gilmore, Richard, Anderson, Jay, Jacoby, Douglas, Harris, Bill, Gardner, Geraldine, Dandillaya, Ramprasad, Vora, Kishor, Kostis, John, Hunter, John, Laxson, David, Ball, Eric, Egydio, Flavia, Kawakami, Anelise, Oliveira, Janaina, Wozniak, Julianna, Matthews, Alexander, Ratky, Caroline, Valiris, Janine, Berdan, Lisa, Hepditch, Anita, Quintero, Kirby, Rorick, Tyrus, Westbrook, Melissa, Pascual, Andrea, Rovito, Carla, Bezault, Madeleine, Drouet, Elodie, Simon, Tabassome, Alsweiler, Caroline, Luyten, Anne, Butters, Julie, Griffith, Liddy, Shaw, Michelle, Grunberg, Lena, Islam, Shahidul, Brégeault, Marie-France, Bougon, Nathalie, Faustino, Douglas, Fontecave, Sylvie, Murphy, Judith, Verrier, Melanie, Veronique Agnetti, Andersen, Dorthe, Badreddine, Emmy, Bekkouche, Mhamed, Bouancheau, Cecile, Brigui, Imane, Brocklehurst, Maddy, Cianciarulo, Joseph, Devaul, Dawn, Domokos, Szilvia, Gache, Cecile, Gobillot, Caroline, Guillou, Severine, Healy, Jan, Heath, Megan, Jaiwal, Gayatri, Javierre, Carine, Labeirie, Julien, Monier, Myriam, Morales, Ulises, Mrabti, Asmaa, Mthombeni, Bicky, Okan, Betim, Smith, Lucile, Sheller, Jennifer, Sopena, Sebastien, Pellan, Valerie, Benbernou, Fadela, Bengrait, Nafissa, Lamoureux, Maud, Kralova, Katarina, Scemama, Michel, Bejuit, Raphael, Coulange, Anthony, Berthou, Christelle, Repincay, Jérôme, Lorenzato, Christelle, Etienne, Alexis, Gouet, Valerie, Loizeau, Virginie, Normand, Mickael, Ourliac, Anne, Rondel, Christelle, Adamo, Antony, Beltran, Pascale, Barraud, Pauline, Dubois-Gache, Helene, Halle, Benjamin, Metwally, Lamia, Mourgues, Maxime, Sotty, Marc, Vincendet, Marion, Cotruta, Raluca, Chengyue, Zhu, Fournie-Lloret, Dominique, Morrello, Christine, Perthuis, Aurelie, Picault, Patrick, Zobouyan, Isabelle, Colhoun, Helen M., Dempsey, Michael A., McClanahan, Mark A., Manvelian, Garen, Sinnaeve, Peter R., and Gabriel Steg, Ph
- Published
- 2021
- Full Text
- View/download PDF
44. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial
- Author
-
Sharma, Abhinav, Ofstad, Anne Pernille, Ahmad, Tariq, Zinman, Bernard, Zwiener, Isabella, Fitchett, David, Wanner, Christoph, George, Jyothis T., Hantel, Stefan, Desai, Nihar, and Mentz, Robert J.
- Published
- 2021
- Full Text
- View/download PDF
45. Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults
- Author
-
Patel, Kershaw V., Simek, Shawn, Ayers, Colby, Neeland, Ian J., deFilippi, Christopher, Seliger, Stephen L., Lonergan, Katy, Minniefield, Nicole, Mentz, Robert J., Correa, Adolfo, Yimer, Wondwosen K., Hall, Michael E., Rodriguez, Carlos J., de Lemos, James A., Berry, Jarett D., and Pandey, Ambarish
- Published
- 2021
- Full Text
- View/download PDF
46. Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure
- Author
-
Pandey, Ambarish, Keshvani, Neil, Zhong, Lin, Mentz, Robert J., Piña, Ileana L., DeVore, Adam D., Yancy, Clyde, Kitzman, Dalane W., and Fonarow, Gregg C.
- Published
- 2021
- Full Text
- View/download PDF
47. Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial
- Author
-
Adams, Kirkwood, Long, Tammy, Bhatt, Kunal, Walker, Brandon, DeWald, Tracy, Biever, Kim, Axsom, Kelly, Acosta, Ariana, Murthy, Sandhya, Camilo, Angeline, Rich, Jonathan D., Martinez, Leslie, Testani, Jeffrey M., Tainsh, Jennifer, Smith, Bryan, Bennett, Amy, Vader, Justin, Stilinovic, Stephanie, McCulloch, Michael, Musso, Iris, Skopicki, Hal, Caikauskaite, Indre, Psotka, Mitchell A., Freiler, Allen, Heroux, Alain, Kartje, Carol, Lala-Trindade, Anuradha, Julien, Lovelyne, Stevens, Gerin, Leppla, Keriann, Tang, Wilson, Fonk, Teresa, Lev, Yair, Fizgerald, Kathleen, William, Preethi, Stroster, John, Eberly, Arthur, III, Workman, Celeste, Gottlieb, Stephen, Bowers-Lash, Mary, Haught, Walter Herbert, Abath, Cynthia, Grafton, Gillian, Neaton, Kelsey, Larned, Joshua, Ortiz, Mara-Li, Tejwani, Lokesh, Villalta, Tara, Mody, Freny, Strugatsky, Svetlana, Krim, Selim, Washington, Katasha, Robinson, Monique, Norton, Nadine, Smart, Frank, Worsham, Emily, Fang, James, Goldstein, Joe, Dunlap, Stephanie, Starnes, Nancy, Adler, Alexander, Theodorof, Virginia, Bell, Adrian, Kondramashin, Aleksey, Banerjee, Dipanjan, Yee, Michael, Ruiz-Duque, Ernesto, Larew, Cynthia, Mizyed, Ahmad, Sawaya, Kara, Friedman, Dennis, Rele, Shilpa, Rommel, John, Burkhart, Janet, Arhinful, Justice, Atkinson, Sam, Goyal, Parag, Samdani, Nidha, Hall, Michael, Watson, Connie, Hummel, Scott, Wells, Joanna, Shetty, Sanjay, White, Jackie, Haas, Donald, Marchand, Colleen, Vilaro, Juan, Osman, Alfaroug, Alexy, Tamas, Dicken, Julie, Guglin, Maya, Willig, Meghan, Ferguson, Andrew, Peabody, Mark, Herre, John, McMichael, Brittany, Clark, John, Britton, Nancy, Ambrosy, Andrew P., Tan, Thida, Heitner, John, Meykler, Marcella, Meadows, Judith, Halliday, Janet, Greene, Stephen J., Velazquez, Eric J., Anstrom, Kevin J., Eisenstein, Eric L., Sapp, Shelly, Morgan, Shelby, Harding, Tina, Sachdev, Vandana, Ketema, Fassil, Kim, Dong-Yun, Desvigne-Nickens, Patrice, Pitt, Bertram, and Mentz, Robert J.
- Published
- 2021
- Full Text
- View/download PDF
48. Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure
- Author
-
Blumer, Vanessa, Greene, Stephen J., Wu, Angie, Butler, Javed, Ezekowitz, Justin A., Lindenfeld, JoAnn, Alhanti, Brooke, Hernandez, Adrian F., O’Connor, Christopher M., and Mentz, Robert J.
- Published
- 2021
- Full Text
- View/download PDF
49. Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure
- Author
-
Fudim, Marat, Patel, Manesh R., Boortz-Marx, Richard, Borlaug, Barry A., DeVore, Adam D., Ganesh, Arun, Green, Cynthia L., Lopes, Renato D., Mentz, Robert J., Patel, Chetan B., Rogers, Joseph G., Felker, G. Michael, Hernandez, Adrian F., Sunagawa, Kenji, and Burkhoff, Daniel
- Published
- 2021
- Full Text
- View/download PDF
50. Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes Findings From the ASCEND-HF Trial
- Author
-
Ambrosy, Andrew P, Cerbin, Lukasz P, Armstrong, Paul W, Butler, Javed, Coles, Adrian, DeVore, Adam D, Dunlap, Mark E, Ezekowitz, Justin A, Felker, G Michael, Fudim, Marat, Greene, Stephen J, Hernandez, Adrian F, O'Connor, Christopher M, Schulte, Philip, Starling, Randall C, Teerlink, John R, Voors, Adriaan A, and Mentz, Robert J
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Heart Disease ,Clinical Research ,Cardiovascular ,Clinical Trials and Supportive Activities ,Acute Disease ,Aged ,Dyspnea ,Female ,Heart Failure ,Hospitalization ,Humans ,Male ,Middle Aged ,Natriuretic Agents ,Natriuretic Peptide ,Brain ,Treatment Outcome ,Urine ,Weight Gain ,Weight Loss ,acute heart failure ,body weight ,dyspnea ,urine output ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
ObjectivesThis study sought to examine the relationships between in-hospital and post-discharge body weight changes and outcomes among patients hospitalized for acute heart failure (AHF).BackgroundBody weight changes during and after hospitalization for AHF and the relationships with outcomes have not been well characterized.MethodsA post hoc analysis was performed of the ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure) trial, which enrolled patients admitted for AHF regardless of ejection fraction. In-hospital body weight change was defined as the difference between baseline and discharge/day 10, whereas post-discharge body weight change was defined as the difference between discharge/day 10 and day 30. Spearman rank correlations of weight change, urine output (UOP), and dyspnea relief as assessed by a 7-point Likert scale are described. Logistic and Cox proportional hazards regression was used to evaluate the relationship between weight change and outcomes.ResultsStudy participants with complete body weight data (n = 4,172) had a mean age of 65 ± 14 years, and 66% were male. Ischemic heart disease was reported in 60% of patients and the average ejection fraction was 30 ± 13%. The median change in body weight was -1.0 kg (interquartile range: -2.1 to 0.0 kg) at 24 h and -2.3 kg (interquartile range: -5.0 to -0.7 kg) by discharge/day 10. At hour 24, there was a weak correlation between change in body weight and UOP (r = -0.381), and minimal correlation between body weight change and dyspnea relief (r = -0.096). After risk adjustment, increasing body weight during hospitalization was associated with a 16% increase per kg in the likelihood of 30-day mortality or HF readmission for patients showing weight loss ≤1 kg or weight gain during hospitalization (odds ratio per kg increase 1.16, 95% confidence interval [CI]: 1.09 to 1.27; p < 0.001). Among the subset of patients experiencing >1-kg increase in body weight post-discharge, increasing body weight was associated with higher risk of 180-day mortality (hazard ratio per kg increase 1.16; 95% CI: 1.09 to 1.23; p < 0.001).ConclusionsA substantial number of patients experienced minimal weight loss or frank weight gain in the context of an AHF trial, and increasing body weight in this subset of patients was independently associated with a worse post-discharge prognosis.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.